Alcoholic liver disease articles from across Nature Portfolio

Díaz et al. estimate the prevalence of steatotic liver disease (SLD) in adults in the United States. Increased waist circumference, excess weight, abnormal glucose metabolism, and hypertension are associated with a higher risk of advanced fibrosis in SLD, with sex, hispanic ethnicity and lack of health insurance associated with certain types.

It is elusive why some heavy drinkers progress to severe alcohol-related liver disease (ALD) while others do not. Here we show that people who have a poor diet, as indicated with a data-driven score, might be more susceptible to severe ALD due to alcohol consumption.

In this study, IL-37d has been evidenced to bind lysosomal Rheb and suppress its activation in mTORC1 independent of TSC2. In hepatocyte, IL-37d is responsively decreased by ethanol and the recombinant TAT-rh-IL-37d protein improves alcohol-induced liver disorders via Rheb-mTORC1 axis.

Consumption of no and low-alcohol (NoLo) beverages is now commonplace in modern society. However, the debate surrounding the relative risks and benefits of these products is nuanced and evolving, particularly in patients with a history of alcohol use disorder or alcohol-related liver disease. This Comment summarizes the major individual and public health implications of NoLo drinks in order to help inform our interactions with these patient groups.

An expert panel has proposed 28 recommendations for the design and conduct of clinical trials for alcohol use disorders and alcohol-associated liver disease. This field has a scarcity of clinical trials, despite alcohol abuse and alcohol-related liver disease being one of the greatest causes of morbidity and mortality worldwide.

In 2023, there were significant advancements in trials of interventions to reduce mortality and morbidity from alcohol-related liver disease, spanning the entire spectrum of disease: primary prevention to reduce overall alcohol-related harm, secondary prevention to attenuate fibrosis progression and tertiary prevention using antibiotics for severe alcohol-associated hepatitis.